Articles tagged with Intravenous Injections
Scientists developed an injectable therapy that protects the heart from damage after a heart attack by blocking the interaction between two proteins, Keap1 and Nrf2. The study showed decreased inflammation, cell death, and improved cardiac function in animal models.
Ferric carboxymaltose did not significantly reduce time to first heart failure hospitalization or cardiovascular death in patients with heart failure and iron deficiency. The treatment also did not reduce total number of heart failure hospitalizations compared to placebo.
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
A team of researchers developed a wearable camera system that uses artificial intelligence to detect potential medication delivery errors. The AI achieved high sensitivity and specificity in identifying vial-swap errors, making it a critical safeguard in operating rooms, intensive-care units, and emergency-medicine settings.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
A UofL cardiologist is leading a Phase II clinical trial of a new stem cell therapy for heart failure, the first in the US to use intravenous delivery. The trial aims to determine whether one or multiple doses of mesenchymal stem cells improve health and quality of life for patients.
Intravenous thrombolysis (IVT) plus thrombectomy demonstrates significant benefits over thrombectomy alone when administered within a short timeframe after symptom onset. This study, based on individual participant data from six randomized clinical trials, found IVT before thrombectomy to be time-dependent and statistically significant.
A phase II clinical trial found Muse cell-based product CL2020 to be highly tolerated and improved ALS symptoms, but may not halt disease progression. The treatment's efficacy depends on combining it with other drugs for future treatments.
A study published at the American Stroke Association's International Stroke Conference 2024 found that treating people with ischemic stroke with intravenous injections of a combination of biologically active components of ginkgo biloba during the first two weeks after the stroke improved early cognitive recovery. The treatment, called ...
Researchers developed a new intravenous needle that softens via body temperature on insertion, reducing tissue damage and blood-borne disease risks. The P-CARE needle's variable stiffness characteristics make it flexible upon insertion, allowing for more comfortable injections.
Researchers developed a promising strategy to reduce adverse reactions to nanoparticles by using complement inhibitors. The study showed that regulators being studied effectively inhibited complement activation by nanoparticles in human serum in vitro and animal models.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
Researchers at the University of Maryland School of Medicine found that monoclonal antibody CIS43LS provided high levels of protection against controlled human malaria infection. The study's findings suggest that this treatment could be a potential game changer for deploying monoclonal antibody therapies in African countries.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
Researchers at Hokkaido University created a lipid polymer that can carry genetic code into lung cells, potentially treating diseases such as acute respiratory distress syndrome and lung cancers. The delivery method bypasses the liver and targets specific lung cells without targeting ligands.